<h1>Pharma campaign framing menstrual pain as public health issue raises regulatory, consumer protection and privacy compliance concerns</h1> A pharmaceutical company launched a national awareness initiative addressing dysmenorrhea, asserting it affects about 80% of Indian girls and women and arguing that normalization of menstrual pain leads to underdiagnosis of conditions like endometriosis, adenomyosis and fibroids. The campaign promotes education, empowerment and an informational website with testimonials and expert content, positioning excessive period pain as a public-health concern rather than a private symptom. Legal considerations include potential regulatory scrutiny of medical claims, consumer protection issues if efficacy or prevalence figures are overstated, and privacy/data compliance for user-submitted content on the campaign platform.